Literature DB >> 19766459

The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.

David L Penn1, Richard S E Keefe, Sonia M Davis, Piper S Meyer, Diana O Perkins, Diane Losardo, Jeffrey A Lieberman.   

Abstract

Few pharmacological intervention studies have examined the impact of medication on social cognition, particularly emotion perception. The goal of this randomized, double-blind study is to compare the effects of several second generation antipsychotics and a first generation antipsychotic, perphenazine, on emotion perception in individuals with schizophrenia. Patients were assigned to receive treatment with olanzapine, queitapine fumarate, risperidone, ziprasidone or perphenazine for up to 18 months. Eight hundred and seventy three patients completed an emotion perception test immediately prior to randomization and after 2 months of treatment. We also examined baseline predictors of emotion perception change. Most treatments were associated with a small, non-statistically significant improvement in emotion perception at two months, although they did not differ from one another. Greater improvement in emotion perception at 2 months was significantly predicted by lower baseline emotion perception and higher baseline neurocognitive functioning, and marginally predicted by less time on an antipsychotic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19766459      PMCID: PMC2765056          DOI: 10.1016/j.schres.2009.08.016

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  30 in total

Review 1.  The neurobiology of social cognition.

Authors:  R Adolphs
Journal:  Curr Opin Neurobiol       Date:  2001-04       Impact factor: 6.627

2.  The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

Authors:  Keith H Nuechterlein; Michael F Green; Robert S Kern; Lyle E Baade; Deanna M Barch; Jonathan D Cohen; Susan Essock; Wayne S Fenton; Frederick J Frese; James M Gold; Terry Goldberg; Robert K Heaton; Richard S E Keefe; Helena Kraemer; Raquelle Mesholam-Gately; Larry J Seidman; Ellen Stover; Daniel R Weinberger; Alexander S Young; Steven Zalcman; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

Review 3.  Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.

Authors:  P D Harvey; R S Keefe
Journal:  Am J Psychiatry       Date:  2001-02       Impact factor: 18.112

4.  Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

Authors:  Marvin S Swartz; Diana O Perkins; T Scott Stroup; Sonia M Davis; George Capuano; Robert A Rosenheck; Fred Reimherr; Mark F McGee; Richard S E Keefe; Joseph P McEvoy; John K Hsiao; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2007-03       Impact factor: 18.112

5.  Modification of affect perception deficits in schizophrenia.

Authors:  D L Penn; D Combs
Journal:  Schizophr Res       Date:  2000-12-15       Impact factor: 4.939

6.  Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning.

Authors:  Philip D Harvey; Thomas L Patterson; Larry S Potter; Kate Zhong; Martin Brecher
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

7.  Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.

Authors:  Mark J Sergi; Michael F Green; Clifford Widmark; Christopher Reist; Stephen Erhart; David L Braff; Kimmy S Kee; Stephen R Marder; Jim Mintz
Journal:  Am J Psychiatry       Date:  2007-10       Impact factor: 18.112

8.  Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.

Authors:  Richard S E Keefe; Anil K Malhotra; Herbert Y Meltzer; John M Kane; Robert W Buchanan; Anita Murthy; Mindy Sovel; Chunming Li; Robert Goldman
Journal:  Neuropsychopharmacology       Date:  2007-07-11       Impact factor: 7.853

Review 9.  Emotion recognition via facial expression and affective prosody in schizophrenia: a methodological review.

Authors:  Jane Edwards; Henry J Jackson; Philippa E Pattison
Journal:  Clin Psychol Rev       Date:  2002-07

10.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Authors:  T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Matthew J Byerly; Ira D Glick; Jose M Canive; Mark F McGee; George M Simpson; Michael C Stevens; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

View more
  27 in total

Review 1.  Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.

Authors:  Kazuto Oya; Yuki Matsuda; Shinji Matsunaga; Taro Kishi; Nakao Iwata
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-25       Impact factor: 5.270

2.  Effects of Oxytocin on Neural Response to Facial Expressions in Patients with Schizophrenia.

Authors:  Na Young Shin; Hye Yoon Park; Wi Hoon Jung; Jin Woo Park; Je-Yeon Yun; Joon Hwan Jang; Sung Nyun Kim; Hyun Jung Han; So-Yeon Kim; Do-Hyung Kang; Jun Soo Kwon
Journal:  Neuropsychopharmacology       Date:  2015-02-10       Impact factor: 7.853

3.  Adapting social neuroscience measures for schizophrenia clinical trials, Part 1: ferrying paradigms across perilous waters.

Authors:  Michael F Green; Junghee Lee; Kevin N Ochsner
Journal:  Schizophr Bull       Date:  2013-09-26       Impact factor: 9.306

4.  The effect of emotional context on facial emotion ratings in schizophrenia.

Authors:  Yu Sun Chung; Deanna M Barch
Journal:  Schizophr Res       Date:  2011-06-29       Impact factor: 4.939

5.  Restricted attention to social cues in schizophrenia patients.

Authors:  Alexandra Nikolaides; Susanne Miess; Isabella Auvera; Ralf Müller; Joachim Klosterkötter; Stephan Ruhrmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-06-15       Impact factor: 5.270

6.  A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia.

Authors:  L Fredrik Jarskog; Cort A Pedersen; Jacqueline L Johnson; Robert M Hamer; Shane W Rau; Tonya Elliott; David L Penn
Journal:  Schizophr Res       Date:  2017-01-13       Impact factor: 4.939

7.  Altered age-related trajectories of amygdala-prefrontal circuitry in adolescents at clinical high risk for psychosis: a preliminary study.

Authors:  Dylan G Gee; Katherine H Karlsgodt; Theo G M van Erp; Carrie E Bearden; Matthew D Lieberman; Aysenil Belger; Diana O Perkins; Doreen M Olvet; Barbara A Cornblatt; Todd Constable; Scott W Woods; Jean Addington; Kristin S Cadenhead; Thomas H McGlashan; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Tyrone D Cannon
Journal:  Schizophr Res       Date:  2011-11-06       Impact factor: 4.939

8.  A meta-analysis of emotion perception and functional outcomes in schizophrenia.

Authors:  Farzin Irani; Sarah Seligman; Vidyulata Kamath; Christian Kohler; Ruben C Gur
Journal:  Schizophr Res       Date:  2012-02-15       Impact factor: 4.939

Review 9.  Perphenazine for schizophrenia.

Authors:  Benno Hartung; Stephanie Sampson; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2015-03-06

10.  Reversal of social deficits by subchronic oxytocin in two autism mouse models.

Authors:  Brian L Teng; Viktoriya D Nikolova; Natallia V Riddick; Kara L Agster; James J Crowley; Lorinda K Baker; Beverly H Koller; Cort A Pedersen; Michael B Jarstfer; Sheryl S Moy
Journal:  Neuropharmacology       Date:  2015-12-31       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.